exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087773 RNA Name: hsa-miR-143-3p RNA Type: miRNA Chromosome: chr5 Starnd: + Coordinate: Start Site(bp): 149428978 End Site(bp): 149428998 External Links: hsa-miR-143-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACVR1B chr12 51951699 51997078 + BTF3L4 chr1 52056199 52090716 + BTG2 chr1 203305491 203309602 + CAPZB chr1 19338775 19485539 - CDK6 chr7 92604921 92836594 - CELSR2 chr1 109249539 109275751 + CIT chr12 119685791 119877320 - DEGS1 chr1 224175756 224193441 + DYRK1B chr19 39825350 39834201 - EFNA3 chr1 155078837 155087538 + FOSL2 chr2 28392448 28417317 + IGFBP5 chr2 216672105 216695549 - KRIT1 chr7 92198969 92246166 - MAP3K3 chr17 63622415 63696303 + NES chr1 156668763 156677407 - PACS1 chr11 66070272 66244744 + PATL1 chr11 59636716 59669037 - PNKD chr2 218270392 218346793 + RFWD3 chr16 74621399 74666877 - SLC7A11 chr4 138164097 138242349 - SON chr21 33543038 33577481 + STARD4 chr5 111496033 111512590 - STMN3 chr20 63639705 63657682 - TATDN2 chr3 10248023 10281218 + TFPI chr2 187464230 187565760 - TIGD5 chr8 143597831 143603224 + VPS37C chr11 61130257 61161615 - WSB1 chr17 27294076 27315926 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001247 chr22 46125304 46136418 + hsa_circ_0000711 chr16 68155889 68160513 + hsa_circ_0000431 chr12 102301963 102308010 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009022.1 chr16 69976297 70065948 - AC091564.7 chr11 6610883 6616594 - AC245884.8 chr19 54438665 54439544 - DHRS4-AS1 chr14 23938219 24052555 - LINC00667 chr18 5237826 5290608 + LZTS1-AS1 chr8 20275773 20290458 + MALAT1 chr11 65497688 65506516 + MCM3AP-AS1 chr21 46229196 46259390 + OIP5-AS1 chr15 41283990 41309737 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.